MAM14 Immunotherapy New Modality Treat Autoimmune Disorder
Keywords:
MAM14 immunotherapy, PBL, IDDM, RA, MS and anterior uveitis, autoreactive T cells, regulatory T cells, Shedding antigens and conventional immunosuppressant's.Abstract
There is no safe single treatment for autoimmune disorders until this writing. This new modality is challenging this notion with safe no toxic method named MAM14 immunotherapy. This new method have been tried on several types of autoimmune disorders in the last 25 years in our lab at Kuwait University Faculty of Medicine. In this article we demonstrate the difference of MAM14 on four out of the 14 autoimmune disorder studied compared to control who received conventional chemotherapy. Data accumulated of 1400 patients compared to 1400 controls. For the present article the sample we chose 10 patients treated with MAM14 for each disease studied compared to 10 control- patients from the same sickness but treated by conventional immunosuppressant chemotherapy, Cyclosporine, Methotrexate ,Tacrolimus or steroid. MAM14 immunotherapy In brief is vaccination of patients by allogeneic stressed peripheral blood lymphocytes. Peripheral Blood Lymphocytes isolated from venous whole blood on Ficoll-Paque centrifugation.
Cultured for 24 hours in sterile physiological enriched media. Vaccinated subcutaneously into forearm of patients. Vaccination given every 4 weeks for four visits. 4 autoimmune disorder included in this study namely insulin dependent diabetes mellitus, rheumatoid arthritis, multiple sclerosis and anterior uveitis. Total 40 patients- treated by MAM14 method 10 patients of each disease compared to 10 control patients of the same disorder but on conventional chemotherapy. Prism Graph pad biostatistical package was used for data analysis. Data accumulated showed significant improvement in signs and symptoms of the present autoimmune disorders studied. Namely insulin dependent diabetes mellitus, rheumatoid arthritis, multiple sclerosis and anterior uveitis. MAM14 immunotherapy showed superior improvement and safety on the long run compared to control patients who receive conventional immunosuppressant.
Mechanism postulated that culturing cells in vitro cause shedding of antigens, these antigens direct autoreactive pathogenic T cells convert to regulatory protective T cells in the presence of peripheral stem cells leading to restoring tolerance and switching off autoimmunity reaction.
References
[2] Roitts Essential Immunology textbook. 12th edition, Peter j. Delves,Seamus , J. martin,Dennis , R. Burton, Ivan m. Roitt.
[3] Parslow , Stites , Terr and Imboden . Medical Immunology tenth edition. LANGE medical book McGraw-Hill. 2001.
[4] Saleh A Alharbi, Ali S Alharbi. IgA Nephropathy improved by MAM14 immunotherapy. American scientific Research journal (ASRJETS) 2015 in (press).
[5] Saleh A Alharbi, Ali S Alharbi. MAM14 immunotherapy can treat autoimmune uveitis. ASRJETS 2015 (in press)
[6] Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003; 2:47388.
[7] Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370:186174.
[8] Mark Mccarty, Saleh A Alharbi, Vaccination with heat-shocked mononuclear cells as a strategy for treating neurodegenerative disorders driven by microglial inflammation. Medical Hypotheses, vol 81, (5) pages 773-776. November 2013.
[9] Alharbi, Saleh: MAM 14 new modality in treating autoimmune disorders.Discussing mechanism. Guest speaker in First international conference in Allergology and immunology controversies. Sorrento, Italy, April 29 May 1 2010.
[10] Alharbi, S.A., Levy, E.M. Depression of the Immune Response in Trauma Victims. 8th New England Immunology Conference, Oct. 23-24, 1982. Marine Biological Laboratory, Woods Hole, Massachusetts, U.S.A.
[11] Levy, E.M., Alharbi, S.A., Horland, A.A. Changes in T-Cell Subpopulations and Function after Trauma. Immunobiol. 1982; 163: 377.
[12] Levy, E.M., Alharbi, S.A., Black, P.H. A Decrease in T-4 Cells with Accompanying Rise in Null Cells in Trauma Patients. N. Eng. J. Med. 1983; 309(2): 110.
[13] Levy, E.M., Alharbi, S.A., Black, P.H. Phenotypic Changes in Lymphocyte Subset in the First Week after Severe Multiple Trauma in the Pathophysiology of Combined Injury and Trauma. Bethesda, Maryland, U.S.A.
[14] Alharbi, S.A. Immunocompromise and Physiologic Alterations in Critically Injured Patients. ( Dissertation). Boston University Medical Center. Sept. 1984.
[15] Levy, E.M., Alharbi, S.A., Grindlinger, G., Black, P.H. Changes in Mitogen Responsiveness of Lymphocyte after Traumatic Injury: Relation to Development of Sepsis. Clin. Immunol. Immunopathol. 1984; 32(2): 224-33.
[16] Fouad, F., Johny, K.V., Kaaba, S.A., Alkarmi, T.O., Sharma, P., Alharbi, S.A. MHC in SLE: A Study on a Kuwaiti Population. Eur. J. Immunogen. 1994; 21: 11-14.
[17] Alharbi, S.A., Fouad, F., Kaaba, S.A. The First HLA Anthropological Study in the Kuwaiti Population. Eur. J. Immunogen. 1994; 21: 295-300.
[18] Alharbi, S.A., Fouad, F., Kaaba, S.A., El-Tomi, N. Conversion from Cyclosporine to FK-506 in Liver Allograft Rejection in Kuwait. Med. Prin. Prac. 1994; 3: 199-203.
[19] Alharbi, S. A., A. Al-arbash, M., Fouad, F., Kaaba, S.A., Mousa, M.A., Al-Fouzan. A Study of HLA Class I/II and T lymphocyte Subsets in Kuwaiti Vitiligo Patients. Eur. J. Immunogen. 1995; 22: 209-13.
[20] Kaaba S.A., Alharbi, S. A. Abnormal Lymphocyte Subsets in Kuwaiti Patients with IDDM and Their First-Degree Relatives. Immunol. Letters 1995; 47: 209-13.
[21] Alharbi, S.A., Mahmoud, F.F. Assoication of MHC Class I with Spondyloarthropathy in Kuwait. Eur. J. of Immunogen. 1996; 23: 67-70.
[22] Mahmoud, F., Alharbi, S. A., McCabe, M., Haines, D.D., Burleson, J.A., Kreutzer, D.L. Abnormal Lymphocyte Surface Antigen Expression in Peripheral Blood of a Kuwaiti Population (after Iraqi invasion). Ann. N.Y. Acad. Sci. 1996; 793: 498-503.
[23] Alharbi, S.A., Haines, D.D. Immunotherapeutic Management of IDDM: Report of Preliminary Human Clinical Trial. Fund. Clin. Pharm. 1999; 13 (Supp. 1):169s.
[24] Alharbi , S A & Haines, DD. MAM 14 IMMUNOTHERAPY IN TREATMENT OF CERTAIN AUTOIMMUNE DISORDERS. SUBMETTED TO 6th NEW TRENDS IN IMMUNOSUPPRESSION CONFERENCE. 2004. Austria.
[25] Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:2358.
[26] Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA (1998) An essential role for ectodomain shedding in mammalian development . Science 282: 1281–1284.
[27] Paul H Black personal communication. BUMC, 1995.
Downloads
Published
How to Cite
Issue
Section
License
Authors who submit papers with this journal agree to the following terms.
